Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.  

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France
    Gentaur Germany

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

     

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA
    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    Wednesday, 10 April 2013 00:00

    Duloxetine reduces painful neuropathy

    Rate this item
    (1 Vote)

    gene-modification-elisa-pcr-equrpment-monoclonal-antiAntidepressant duloxetine effectively treat peripheral neuropathy induced by chemotherapy showed a phase III clinical study published in the Journal of the American Medical Association.

    According to Ellen Smith of the University of Michigan in Ann Arbor, after 5 weeks of treatment, patients receiving duloxetine experienced a significant reduction in morbidity compared with placebo.

    Peripheral neuropathy occurs in 20-40% of patients treated with neurotoxic chemotherapy. Such fees are (paclitaxel, docetaxel, etc.)., Vinca alkaloids (vincristine, vinblastine) and platinum compounds (cisplatin, oxaliplatin, etc.).. The condition can persist for years after treatment and greatly reduced quality of life.

    Previous studies have shown that inhiborite reuptake of serotonin and norepinephrine (class of antidepressants) have the potential to influence the state. Duloxetine also is known to reduce morbidity and diabetic neuropathy.

    In order to clarify the properties of duloxetine, the researchers conducted a randomized, double-blind, placebo-controlled study in 220 patients with stage I or greater sensory neuropathy induced by anti-cancer therapy. All participants were over the age of 25 and assessed their painful 10-ball standard scale, three months after the completion of a chemotherapy course. Half the patients received duloxetine and half - placebo, allocation is done randomly. The soreness was re-assessed after the study.

    The end result of the study shows that 5-week treatment with duloxetine significantly reduces morbidity in peripheral neuropathy. This, in turn, enhances the quality of life and employability of patients. The benefits of duloxetine seem greatest for people who have completed chemotherapy with platinum compounds.

    The most common side effects of duloxetine documented during the study were fatigue, insomnia and nausea.
     
    Although good design of the study does not include follow-up of patients for an extended period, so it is impossible to tell how lasting are the effects of duloxetine in this indication.

    Read 2400 times